Key Insights
The Canada diabetes care devices market, valued at $540 million in 2025, is projected to experience robust growth, driven by a rising prevalence of diabetes, an aging population, and increasing awareness of advanced diabetes management technologies. The market's Compound Annual Growth Rate (CAGR) of 4.75% from 2025 to 2033 indicates a significant expansion over the forecast period. Key growth drivers include the increasing adoption of continuous glucose monitoring (CGM) systems, which offer real-time glucose data empowering patients to make informed decisions about insulin management. The demand for insulin pumps and related accessories is also expected to rise, propelled by technological advancements offering improved usability and features. Furthermore, the increasing availability of sophisticated data management software linked to devices further enhances patient care and assists healthcare providers in optimizing treatment strategies. The market is segmented into various device types, including glucose monitoring systems (CGM and self-monitoring blood glucose (SMBG) devices), insulin delivery systems (pumps and pens), and other ancillary devices like lancets and test strips. Competition in the market is intense, with major players like Medtronic, Abbott, and Novo Nordisk vying for market share through innovation and strategic partnerships. While the increasing cost of diabetes care poses a restraint, the long-term benefits and improved quality of life offered by advanced devices are expected to offset this factor, contributing to sustained market growth.
Growth within the Canadian diabetes care devices market will be influenced by government initiatives promoting better diabetes management and improved healthcare access. The increasing emphasis on preventative care and early diagnosis also contributes to market expansion. However, challenges remain, including potential reimbursement hurdles for advanced technologies and the need for continued education to enhance patient understanding and adoption. Nevertheless, the consistent rise in diabetes prevalence and the ongoing technological advancements in diabetes care devices strongly suggest a positive outlook for the Canadian market, with sustained growth anticipated throughout the forecast period. The focus will shift towards integrating technology and data management to provide holistic and personalized diabetes care, driving further innovation and market expansion.
Canada Diabetes Care Devices Market Report: 2019-2033
This comprehensive report provides an in-depth analysis of the Canada Diabetes Care Devices Market, offering valuable insights for stakeholders across the industry. Covering the period from 2019 to 2033, with a base year of 2025 and a forecast period of 2025-2033, this report meticulously examines market structure, competitive dynamics, industry trends, and future growth potential. The analysis includes detailed segmentations across various drug types and devices, including insulin delivery systems, glucose monitoring solutions, and other related products. Key players like Medtronic, Abbott, Novo Nordisk A/S, and Dexcom are thoroughly profiled, providing a complete picture of the market landscape.
Canada Diabetes Care Devices Market Market Structure & Competitive Dynamics
The Canadian diabetes care devices market exhibits a moderately concentrated structure, with a few multinational corporations holding significant market share. However, the presence of several smaller, specialized companies fosters a dynamic and innovative ecosystem. The regulatory framework, governed by Health Canada, plays a crucial role in shaping market access and product approvals, influencing both market entry barriers and the overall competitive landscape. The market witnesses continuous innovation, driven by technological advancements in continuous glucose monitoring (CGM) and insulin delivery systems. The prevalence of substitute therapies and evolving end-user preferences further add to the complexities of the market. Mergers and acquisitions (M&A) activity is relatively moderate but plays a significant role in reshaping market dynamics and consolidating market power. Recent M&A deals, while not publicly disclosed with precise values in this report, suggest a move towards vertical integration and expansion into new therapeutic areas. The average M&A deal value in the past five years is estimated at xx Million. The top five companies currently control an estimated xx% of the market share.
- Market Concentration: Moderately concentrated
- Innovation Ecosystem: Highly dynamic, driven by technological advancements
- Regulatory Framework: Stringent, governed by Health Canada
- Product Substitutes: Presence of alternative therapies influencing market share
- End-User Trends: Growing preference for convenience and accuracy in diabetes management
- M&A Activity: Moderate but strategically impactful
Canada Diabetes Care Devices Market Industry Trends & Insights
The Canada Diabetes Care Devices Market is experiencing robust growth, driven by several key factors. The increasing prevalence of diabetes, particularly type 2 diabetes, in the Canadian population is a significant market driver. Technological advancements, such as the development of more accurate and user-friendly CGM systems and insulin pumps, are also fueling market expansion. Consumer preferences are shifting towards convenient and less invasive methods of diabetes management, creating demand for innovative devices and therapies. The market is characterized by intense competition, with established players and emerging companies vying for market share through product innovation and strategic partnerships. The CAGR for the forecast period (2025-2033) is projected to be xx%, reflecting a significant growth trajectory. Market penetration of CGM systems is expected to increase from xx% in 2025 to xx% by 2033.
Dominant Markets & Segments in Canada Diabetes Care Devices Market
The Canadian diabetes care devices market is segmented based on several factors, with significant variations in market size and growth potential across these segments. While precise regional breakdowns are not available for public disclosure in this specific context, we can assess the dominant segments using publicly available data.
Dominant Segments: Basal or Long-Acting Insulins demonstrate strong market dominance due to their consistent and sustained glycemic control. Continuous Glucose Monitoring (CGM) systems are experiencing rapid growth due to their ability to provide real-time glucose data, improving diabetes management. Insulin pumps also exhibit significant growth potential given their flexibility and enhanced control over insulin delivery.
Key Drivers: The rising prevalence of diabetes, particularly in older age groups, is a crucial factor influencing the market dynamics. Government initiatives focused on diabetes prevention and management are also stimulating growth. The increase in healthcare spending, the rise in disposable income, and improving healthcare infrastructure further contribute to the overall growth of the market. Furthermore, the increased awareness and education regarding diabetes management are influencing consumer behavior, driving the demand for better diabetes care devices.
Dominance Analysis: The market exhibits strong demand for accurate, convenient, and user-friendly devices. The dominance of particular segments is closely tied to factors such as improved efficacy, reduced side effects, and technological advancements. Companies are concentrating on improving device technology and integration with digital health solutions to improve patient adherence and outcomes.
Canada Diabetes Care Devices Market Product Innovations
The Canadian diabetes care devices market is witnessing significant product innovation, characterized by a shift towards advanced CGM systems, miniaturized insulin pumps, and sophisticated data management software. These innovations enhance ease of use, improve accuracy, and facilitate better integration with patients' lifestyles. The focus is on developing closed-loop systems that automate insulin delivery based on real-time glucose readings. Such advancements contribute to improved glycemic control, ultimately leading to better patient outcomes and a reduction in long-term diabetes complications. The competitive advantage in this market hinges on innovation, affordability, and regulatory approval speed.
Report Segmentation & Scope
This report segments the Canada Diabetes Care Devices Market based on several critical parameters including: drug type (Bolus or Fast Acting Insulins, Non-Insulin Injectable drugs, GLP1 receptor agonists, Oral anti-diabetic drugs, SGLT-2 inhibitors, Meglitinide, Dopamine-D2 receptor agonist, Soliqua/Suliqua, Alpha-Glucosidase inhibitors, DPP-4 inhibitors, Traditional Human Insulins, Amylin Analogue, Biguanide, Sulfonylureas, Basal or Long Acting Insulins) and device type (Monitoring Devices, Continuous Glucose Monitoring systems, Management Devices, Insulin Pumps, Self-Monitoring Blood Glucose devices). Each segment's growth projections, market size (in Millions), and competitive dynamics are thoroughly analyzed. The projected growth for each segment varies, with some exhibiting higher growth rates than others, influenced by factors such as technological advancements and evolving treatment guidelines.
Key Drivers of Canada Diabetes Care Devices Market Growth
The growth of the Canada Diabetes Care Devices Market is propelled by several factors. The escalating prevalence of diabetes is a major driver, coupled with an aging population and increasing awareness about the disease. Technological advancements, specifically in CGM and insulin pump technology, are enhancing the accuracy and convenience of diabetes management, boosting demand. Government initiatives supporting diabetes care and favourable reimbursement policies are further accelerating market growth. These factors, combined with the rising disposable income and improving healthcare infrastructure, create a strong foundation for sustained market expansion.
Challenges in the Canada Diabetes Care Devices Market Sector
The Canada Diabetes Care Devices Market faces challenges, including high device costs potentially limiting access for some patients, stringent regulatory requirements creating obstacles for new product launches, and intense competition amongst established players and new entrants. Supply chain disruptions can impact device availability, while the complexities of reimbursement policies may restrict market penetration. Furthermore, ensuring patient adherence to treatment regimens remains an ongoing challenge requiring innovative approaches and patient education initiatives.
Leading Players in the Canada Diabetes Care Devices Market Market
- AgaMatrix Inc
- Terumo
- Roche
- Bayshore Health Care
- Express Scripts
- One Drop
- Eli Lilly
- LMC Diabetes and Endocrinology
- Medtronic
- Ypsomed Holding AG
- Telus Health
- AstraZeneca
- Sanofi Aventis
- Becton Dickinson
- Johnson and Johnson (Lifescan)
- Abbott
- Bristol Myers Squibb
- Novo Nordisk A/S
- Arkray
- Boehringer Ingelheim
- Dexcom
- Ascensia Diabetes Care
Key Developments in Canada Diabetes Care Devices Market Sector
- July 2023: Dexcom, Inc. receives Health Canada approval for its Dexcom G7 Continuous Glucose Monitoring System. This significantly enhances the market's CGM options.
- July 2022: NuGen Medical Devices Inc. secures Health Canada approval for its needle-free insulin injection system (InsuJet), marking a significant advancement in insulin delivery technology.
Strategic Canada Diabetes Care Devices Market Market Outlook
The future of the Canada Diabetes Care Devices Market appears bright, with considerable growth potential fueled by continuing advancements in device technology and the increasing prevalence of diabetes. Strategic opportunities exist for companies focusing on innovative products, improved patient compliance strategies, and cost-effective solutions. Collaboration between healthcare providers, technology developers, and regulatory bodies will be crucial in driving market expansion and ensuring broad access to high-quality diabetes care devices.
Canada Diabetes Care Devices Market Segmentation
-
1. Product Type
- 1.1. Monitoring Devices
- 1.2. Management Devices
-
2. End-Use
- 2.1. Hospitals
- 2.2. Clinics
- 2.3. Home Healthcare
-
3. Geography
- 3.1. Ontario
- 3.2. Quebec
- 3.3. British Columbia
- 3.4. Alberta
- 3.5. Manitoba
- 3.6. Saskatchewan
- 3.7. Nova Scotia
- 3.8. New Brunswick
- 3.9. Newfoundland and Labrador
- 3.10. Prince Edward Island
Canada Diabetes Care Devices Market Segmentation By Geography
- 1. Canada
Canada Diabetes Care Devices Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 4.75% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. ; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies
- 3.3. Market Restrains
- 3.3.1 ; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures
- 3.3.2 Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products
- 3.4. Market Trends
- 3.4.1. The Continuous Glucose Monitoring Devices Segment is Growing at a Significant Pace
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Canada Diabetes Care Devices Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Product Type
- 5.1.1. Monitoring Devices
- 5.1.2. Management Devices
- 5.2. Market Analysis, Insights and Forecast - by End-Use
- 5.2.1. Hospitals
- 5.2.2. Clinics
- 5.2.3. Home Healthcare
- 5.3. Market Analysis, Insights and Forecast - by Geography
- 5.3.1. Ontario
- 5.3.2. Quebec
- 5.3.3. British Columbia
- 5.3.4. Alberta
- 5.3.5. Manitoba
- 5.3.6. Saskatchewan
- 5.3.7. Nova Scotia
- 5.3.8. New Brunswick
- 5.3.9. Newfoundland and Labrador
- 5.3.10. Prince Edward Island
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. Canada
- 5.1. Market Analysis, Insights and Forecast - by Product Type
- 6. Eastern Canada Canada Diabetes Care Devices Market Analysis, Insights and Forecast, 2019-2031
- 7. Western Canada Canada Diabetes Care Devices Market Analysis, Insights and Forecast, 2019-2031
- 8. Central Canada Canada Diabetes Care Devices Market Analysis, Insights and Forecast, 2019-2031
- 9. Competitive Analysis
- 9.1. Market Share Analysis 2024
- 9.2. Company Profiles
- 9.2.1 AgaMatrix Inc
- 9.2.1.1. Overview
- 9.2.1.2. Products
- 9.2.1.3. SWOT Analysis
- 9.2.1.4. Recent Developments
- 9.2.1.5. Financials (Based on Availability)
- 9.2.2 Terumo
- 9.2.2.1. Overview
- 9.2.2.2. Products
- 9.2.2.3. SWOT Analysis
- 9.2.2.4. Recent Developments
- 9.2.2.5. Financials (Based on Availability)
- 9.2.3 Roche
- 9.2.3.1. Overview
- 9.2.3.2. Products
- 9.2.3.3. SWOT Analysis
- 9.2.3.4. Recent Developments
- 9.2.3.5. Financials (Based on Availability)
- 9.2.4 Bayshore Health Care
- 9.2.4.1. Overview
- 9.2.4.2. Products
- 9.2.4.3. SWOT Analysis
- 9.2.4.4. Recent Developments
- 9.2.4.5. Financials (Based on Availability)
- 9.2.5 Express Scripts
- 9.2.5.1. Overview
- 9.2.5.2. Products
- 9.2.5.3. SWOT Analysis
- 9.2.5.4. Recent Developments
- 9.2.5.5. Financials (Based on Availability)
- 9.2.6 One Drop
- 9.2.6.1. Overview
- 9.2.6.2. Products
- 9.2.6.3. SWOT Analysis
- 9.2.6.4. Recent Developments
- 9.2.6.5. Financials (Based on Availability)
- 9.2.7 Eli Lilly
- 9.2.7.1. Overview
- 9.2.7.2. Products
- 9.2.7.3. SWOT Analysis
- 9.2.7.4. Recent Developments
- 9.2.7.5. Financials (Based on Availability)
- 9.2.8 LMC Diabetes and Endocrinology
- 9.2.8.1. Overview
- 9.2.8.2. Products
- 9.2.8.3. SWOT Analysis
- 9.2.8.4. Recent Developments
- 9.2.8.5. Financials (Based on Availability)
- 9.2.9 Medtronic
- 9.2.9.1. Overview
- 9.2.9.2. Products
- 9.2.9.3. SWOT Analysis
- 9.2.9.4. Recent Developments
- 9.2.9.5. Financials (Based on Availability)
- 9.2.10 Ypsomed Holding AG
- 9.2.10.1. Overview
- 9.2.10.2. Products
- 9.2.10.3. SWOT Analysis
- 9.2.10.4. Recent Developments
- 9.2.10.5. Financials (Based on Availability)
- 9.2.11 Telus Health
- 9.2.11.1. Overview
- 9.2.11.2. Products
- 9.2.11.3. SWOT Analysis
- 9.2.11.4. Recent Developments
- 9.2.11.5. Financials (Based on Availability)
- 9.2.12 AstraZeneca
- 9.2.12.1. Overview
- 9.2.12.2. Products
- 9.2.12.3. SWOT Analysis
- 9.2.12.4. Recent Developments
- 9.2.12.5. Financials (Based on Availability)
- 9.2.13 Sanofi Aventis
- 9.2.13.1. Overview
- 9.2.13.2. Products
- 9.2.13.3. SWOT Analysis
- 9.2.13.4. Recent Developments
- 9.2.13.5. Financials (Based on Availability)
- 9.2.14 Becton Dickinson
- 9.2.14.1. Overview
- 9.2.14.2. Products
- 9.2.14.3. SWOT Analysis
- 9.2.14.4. Recent Developments
- 9.2.14.5. Financials (Based on Availability)
- 9.2.15 Johnson and Johnson (Lifescan)
- 9.2.15.1. Overview
- 9.2.15.2. Products
- 9.2.15.3. SWOT Analysis
- 9.2.15.4. Recent Developments
- 9.2.15.5. Financials (Based on Availability)
- 9.2.16 Abbott
- 9.2.16.1. Overview
- 9.2.16.2. Products
- 9.2.16.3. SWOT Analysis
- 9.2.16.4. Recent Developments
- 9.2.16.5. Financials (Based on Availability)
- 9.2.17 Bristol Myers Squibb
- 9.2.17.1. Overview
- 9.2.17.2. Products
- 9.2.17.3. SWOT Analysis
- 9.2.17.4. Recent Developments
- 9.2.17.5. Financials (Based on Availability)
- 9.2.18 Novo Nordisk A/S
- 9.2.18.1. Overview
- 9.2.18.2. Products
- 9.2.18.3. SWOT Analysis
- 9.2.18.4. Recent Developments
- 9.2.18.5. Financials (Based on Availability)
- 9.2.19 Arkray
- 9.2.19.1. Overview
- 9.2.19.2. Products
- 9.2.19.3. SWOT Analysis
- 9.2.19.4. Recent Developments
- 9.2.19.5. Financials (Based on Availability)
- 9.2.20 Boehringer Ingelheim
- 9.2.20.1. Overview
- 9.2.20.2. Products
- 9.2.20.3. SWOT Analysis
- 9.2.20.4. Recent Developments
- 9.2.20.5. Financials (Based on Availability)
- 9.2.21 Dexcom
- 9.2.21.1. Overview
- 9.2.21.2. Products
- 9.2.21.3. SWOT Analysis
- 9.2.21.4. Recent Developments
- 9.2.21.5. Financials (Based on Availability)
- 9.2.22 Ascensia Diabetes Care
- 9.2.22.1. Overview
- 9.2.22.2. Products
- 9.2.22.3. SWOT Analysis
- 9.2.22.4. Recent Developments
- 9.2.22.5. Financials (Based on Availability)
- 9.2.1 AgaMatrix Inc
List of Figures
- Figure 1: Canada Diabetes Care Devices Market Revenue Breakdown (Million, %) by Product 2024 & 2032
- Figure 2: Canada Diabetes Care Devices Market Share (%) by Company 2024
List of Tables
- Table 1: Canada Diabetes Care Devices Market Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Region 2019 & 2032
- Table 3: Canada Diabetes Care Devices Market Revenue Million Forecast, by Product Type 2019 & 2032
- Table 4: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Product Type 2019 & 2032
- Table 5: Canada Diabetes Care Devices Market Revenue Million Forecast, by End-Use 2019 & 2032
- Table 6: Canada Diabetes Care Devices Market Volume K Unit Forecast, by End-Use 2019 & 2032
- Table 7: Canada Diabetes Care Devices Market Revenue Million Forecast, by Geography 2019 & 2032
- Table 8: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Geography 2019 & 2032
- Table 9: Canada Diabetes Care Devices Market Revenue Million Forecast, by Region 2019 & 2032
- Table 10: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Region 2019 & 2032
- Table 11: Canada Diabetes Care Devices Market Revenue Million Forecast, by Country 2019 & 2032
- Table 12: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Country 2019 & 2032
- Table 13: Eastern Canada Canada Diabetes Care Devices Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: Eastern Canada Canada Diabetes Care Devices Market Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 15: Western Canada Canada Diabetes Care Devices Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 16: Western Canada Canada Diabetes Care Devices Market Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 17: Central Canada Canada Diabetes Care Devices Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 18: Central Canada Canada Diabetes Care Devices Market Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 19: Canada Diabetes Care Devices Market Revenue Million Forecast, by Product Type 2019 & 2032
- Table 20: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Product Type 2019 & 2032
- Table 21: Canada Diabetes Care Devices Market Revenue Million Forecast, by End-Use 2019 & 2032
- Table 22: Canada Diabetes Care Devices Market Volume K Unit Forecast, by End-Use 2019 & 2032
- Table 23: Canada Diabetes Care Devices Market Revenue Million Forecast, by Geography 2019 & 2032
- Table 24: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Geography 2019 & 2032
- Table 25: Canada Diabetes Care Devices Market Revenue Million Forecast, by Country 2019 & 2032
- Table 26: Canada Diabetes Care Devices Market Volume K Unit Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Canada Diabetes Care Devices Market?
The projected CAGR is approximately 4.75%.
2. Which companies are prominent players in the Canada Diabetes Care Devices Market?
Key companies in the market include AgaMatrix Inc, Terumo, Roche, Bayshore Health Care, Express Scripts, One Drop, Eli Lilly, LMC Diabetes and Endocrinology, Medtronic, Ypsomed Holding AG, Telus Health, AstraZeneca, Sanofi Aventis, Becton Dickinson, Johnson and Johnson (Lifescan), Abbott, Bristol Myers Squibb, Novo Nordisk A/S, Arkray, Boehringer Ingelheim, Dexcom, Ascensia Diabetes Care.
3. What are the main segments of the Canada Diabetes Care Devices Market?
The market segments include Product Type, End-Use, Geography.
4. Can you provide details about the market size?
The market size is estimated to be USD 5.40 Million as of 2022.
5. What are some drivers contributing to market growth?
; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies.
6. What are the notable trends driving market growth?
The Continuous Glucose Monitoring Devices Segment is Growing at a Significant Pace.
7. Are there any restraints impacting market growth?
; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures. Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products.
8. Can you provide examples of recent developments in the market?
July 2023: Dexcom, Inc. has received approval from Health Canada for their latest Dexcom G7 Continuous Glucose Monitoring System. This advanced system is designed for individuals with diabetes of all types, aged two years and above. Dexcom, Inc. specializes in manufacturing reliable continuous glucose monitoring solutions for people living with diabetes.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3800, USD 4500, and USD 5800 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Canada Diabetes Care Devices Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Canada Diabetes Care Devices Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Canada Diabetes Care Devices Market?
To stay informed about further developments, trends, and reports in the Canada Diabetes Care Devices Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
